Evidence map›Paper›PMID 39199387›Full record

ArticleBiomolecules2024

Charge Variants Characterization of Co-Formulated Antibodies by Three-Dimensional Liquid Chromatography-Mass Spectrometry.

Xiaoqing Jin, Luna Chen, Jianlin Chu, Bingfang He

Abstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaoqing JinCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
Luna ChenCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
Jianlin ChuSchool of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China.
Bingfang HeCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.

Funding

Jiangsu Synergetic Innovation Center for Advanced Bio-Manufacture No. XTC2206National Key Research and Development Program of China 2018YFA0902000
6 · The paper itself

Abstract

Co-formulated antibodies can bring clinical benefits to patients by combining two or more antibodies in a single dosage form. However, the quality analysis of co-formulated antibodies raises additional challenges, compared to individual antibodies, due to the need for accurate analysis of multiple antibodies in one solution. It is extremely difficult to effectively separate the charge variants of the two co-formulated antibodies using one ion exchange chromatography (IEC) method because of their similar characteristics. In this study, a novel method was developed for the charge variants characterization of co-formulated antibodies using three-dimensional liquid chromatography-mass spectrometry (3D-LC-MS). Hydrophobic interaction chromatography (HIC) was used as the first dimension to separate and collect the two co-formulated antibodies. The two collections were then injected into the second-dimension IEC separately for charge variants separation and analysis. Subsequently, the separated charge variants underwent on-line desalting in the third-dimension reverse-phase chromatography (RPC) and subsequent mass spectroscopy analysis. The novel method could simultaneously provide a charge variants ratio and post-translational modification (PTM) data for the two co-formulated antibodies. Therefore, it could be used for release testing and stability studies of co-formulated antibodies, making up for the shortcomings of the existing approaches. It was the first time that charge variants of co-formulated antibodies were characterized by the 3D-LC-MS method, to the best of our knowledge.

Indexed as

Mass SpectrometryAnimalsAntibodies, MonoclonalChromatography, Ion ExchangeChromatography, LiquidChromatography, Reverse-PhaseHumansHydrophobic and Hydrophilic InteractionsLiquid Chromatography-Mass SpectrometryProtein Processing, Post-TranslationalAntibodies, Monoclonal3D-LC-MScharacterizationcharge variantsco-formulated antibodies

Identifiers

PMID39199387
PMCPMC11352451

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.